3524 POSTER High rate of clinical benefit response in patients with advanced biliary tract cancer receiving gemcitabine plus capecitabine. A prospective, multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 44/02)

✍ Scribed by D. Koeberle; P. Saletti; M. Borner; C. Caspar; F. Strasser; T. Ruhstaller; O. Mora; D. Dietrich; D. Gerber; R. Herrmann

• Book ID: 118625869
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 58 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)71027-3